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 2 
Abstract 23 
Acute kidney injury (AKI) is a frequent complication of cardiac surgery, which can lead to 24 
higher mortality and long-term renal function impairment. The effect of perioperative renin-25 
angiotensin system inhibitors (RASi) therapy on AKI incidence in patients undergoing cardiac 26 
surgery remains controversial. We reviewed related studies in PubMed, Scopus, and Cochrane 27 
Library from inception to February 2020. Two randomized controlled trials (RCTs) and 21 cohort 28 
studies were included in the meta-analysis, involving 76,321 participants. The pooled odds ratio 29 
and 95% confidence interval were calculated using the DerSimonian and Laird random-effects 30 
model. The results showed no significant association between perioperative RASi therapy and 31 
postoperative AKI in patients undergoing cardiac surgery. We highlighted the limitations of 32 
existing studies and called for well-designed large-scale RCTs to verify the conclusion. 33 
34 
 3 
Central Picture 35 
 36 
No significant association between RASi and AKI in patients undergoing cardiac surgery 37 
Central Message 38 
Our meta-analysis showed no significant association between perioperative RASi therapy and 39 
postoperative AKI in patients undergoing cardiac surgery. 40 
Perspective Statement 41 
 4 
The effect of perioperative use of RASi on postoperative AKI in patients undergoing cardiac 42 
surgery remains controversial. Our results showed no significant association between RASi and 43 
postoperative AKI. These findings suggested that perioperative RASi management strategies did 44 
not have a statistically significant effect on the postoperative AKI incidence in patients undergoing 45 
cardiac surgery. 46 
  47 
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Introduction 48 
Acute kidney injury (AKI) is a frequent complication of cardiac surgery, which can lead to higher 49 
mortality, long-term renal function impairment, and require more medical resources [1, 2]. Thus, 50 
studying the prevention of postoperative AKI in patients undergoing cardiac surgery has important 51 
implications for clinical care and resource utilization. Renin-angiotensin System inhibitors (RASi), 52 
including angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers 53 
(ARBs), are commonly used in patients undergoing cardiac surgery [3]. It is necessary to evaluate 54 
whether such common drugs play a protective or harmful role for AKI following cardiac surgery. 55 
Until now, the effect of perioperative RASi therapy on renal function in patients undergoing 56 
cardiac surgery remains controversial. Some suggested an increased renin-angiotensin system 57 
activity during cardiopulmonary bypass (CPB), which has a prominent role in hypoperfusion-58 
related renal injury, and RASi could improve renal perfusion by blocking the activity [4]. A cohort 59 
study by Benedetto et al. [4] showed a reduction in the incidence of postoperative AKI when using 60 
ACEIs. However, others suggested that RASi increased the risk of perioperative hypotension, 61 
generating a reduction in renal perfusion pressure, a risk factor for renal dysfunction [5]. A meta-62 
analysis conducted by Yacoub et al. [6] found a harmful effect of preoperative RASi therapy on 63 
postoperative AKI in patients undergoing cardiothoracic surgery. However, their study was limited 64 
by the choice of unadjusted odds ratio (OR) instead of adjusted OR when adjusted OR was 65 
available. 66 
A meta-analysis was performed to explore the effect of perioperative RASi on the renal 67 
outcomes in patients undergoing cardiac surgery. 68 
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Material and Methods 69 
Data Sources and Searches 70 
We searched published studies in PubMed, Scopus, and Cochrane Library from inception to 71 
February 2020, using the combination of the following terms: (‘angiotensin-converting enzyme 72 
inhibitors’ or’ ACEI’ or’ renin-angiotensin system blockade’) and (‘cardiac surgery’ or’ heart 73 
surgery’ or’ coronary artery bypass grafting’ or’ cardiovascular surgery’). We did not use terms 74 
related to kidney because we did not want to restrict to the studies that focused on renal function 75 
only. References from the retrieved articles were searched manually. Figure 1 depicted the 76 
selection process. It should be noted that Benedetto et al. [4, 7] wrote two papers satisfying our 77 
criteria in 2008 and 2010, respectively, and the data in these two papers came from the same source, 78 
i.e., the data used overlapped to some extent. Thus, we only included one of them [4] in our meta-79 
analysis, considering the renal focus of this paper. 80 
Study Selection 81 
The inclusion criteria were as follows: (1) randomized controlled trials (RCTs) or cohort studies 82 
compared the effect of perioperative use of RASi with no RASi undergoing cardiac surgery; (2) 83 
studies reported incidence of AKI, or OR with 95% confidence interval (CI) comparing the AKI 84 
risk in the treatment group and control group; (3) the follow-up period of renal function was either 85 
the in-hospital stay or 30 days. 86 
Data Extraction 87 
A standardized data collection form was used to extract the following information: last name of 88 
the first author, publication year, participants, study design, sample size, drug intervention, AKI 89 
definition, mean age, country, and publication quality. AKI was defined differently by different 90 
authors. The quality of each study was independently evaluated by each investigator using the 91 
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Newcastle–Ottawa scale [10] for cohort studies and Cochrane risk of bias tool for RCTs. 92 
Outcome measures 93 
The outcome in the meta-analysis was the incidence of new-onset postoperative AKI.  94 
Statistical Analysis 95 
We conducted a meta-analysis in all included studies. We also performed subgroup analyses on 96 
different patterns of RASi therapy and different types of RASi, respectively. The OR was used to 97 
evaluate the association of RASi therapy with AKI. They were either directly extracted or 98 
calculated from reported AKI incidence. Statistical heterogeneity was evaluated using the Q test, 99 
which uses the 𝐼𝐼2 statistic to quantify the proportion of the total variation across studies due to 100 
heterogeneity rather than chance. The studies included in the meta-analysis were non-identical in 101 
terms of AKI definition, drug intervention, and participants. Therefore, we used the DerSimonian 102 
and Laird random-effects model for meta-analysis. Publication bias was assessed by Egger’s test 103 
and funnel plot. A p-value < 0.05 was considered statistically significant. All statistical analyses 104 
were conducted using Review Manager 5.3 software from the Cochrane Collaboration. 105 
Results 106 
We retrieved 23 studies that met our criteria and included them in the meta-analysis. In terms 107 
of study design, there were 2 RCTs [11, 12], and the rest were cohort studies. As for the drug 108 
intervention, 19 studies focused on the preoperative use of RASi; van Diepen et al. [11] focused 109 
on preoperative continuation versus withdrawal; Drenger et al. [13] studied both perioperative 110 
therapy (preoperative and postoperative) and postoperative administration; Coca et al. [14] 111 
compared not only preoperative continuation with preoperative withdrawal but also preoperative 112 
use with no RASi. The type of RASi also varied: 13 studies focused on the use of ACEIs, and 113 
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ACEIs/ARBs were administrated in 10 studies. Table 1 described the detailed characteristics of the 114 
included studies. 115 
Study participants 116 
The number of participants ranged from 14 to 10,648; in total, 76,321 patients were included. 117 
In terms of surgery type, eight studies focused on coronary artery bypass graft (CABG) surgeries 118 
[4, 5, 13, 16, 17, 25, 32, 35]; one focused on aortic surgery [29]; the remaining studies included 119 
more than one type of surgeries. Among all of the studies, five mentioned the use of CPB in all 120 
patients [4, 13, 28, 31, 36]. Three studies restricted patients to age ≥ 18 and one to ≥ 65. 121 
Perioperative use of RASi and postoperative AKI 122 
Twenty-three articles were included in this meta-analysis. The random-effects model was used 123 
due to high heterogeneity (𝐼𝐼2 = 82%). The pooled OR of postoperative AKI in patients taking 124 
RASi perioperatively was 1.02 (95% CI: 0.89-1.17), with the forest plot shown in Figure 2. This 125 
result showed no significant association of perioperative use of RASi with increased or decreased 126 
risk of postoperative AKI. 127 
Pattern of RASi therapy and postoperative AKI 128 
Subgroup meta-analysis was performed in two different patterns of RASi therapy: preoperative 129 
use of RASi versus no RASi, and preoperative continuation versus preoperative discontinuation. 130 
Additionally, one study reported postoperative use of RASi versus no RASi. The results might help 131 
to decide the initiation or withdrawal of RASi during the procedure of cardiac surgery. 132 
Nineteen studies compared patients taking RASi preoperatively with patients receiving no RASi 133 
therapy. The forest plot was shown in Figure 3. A random-effect model was used considering the 134 
high heterogeneity (𝐼𝐼2 = 84%), and the pooled OR was 1.02 (95% CI: 0.88-1.18). No significant 135 
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association between the preoperative use of RASi and postoperative AKI was found. 136 
For patients chronically taking RASi, two studies compared the continuation of RASi with 137 
discontinuation just before cardiac surgery. The meta-analysis of these two studies [11, 14] 138 
demonstrated no evidence of increased or decreased risk of AKI when withdrawing RASi before 139 
surgery (Figure S1), with the pooled OR being 1.12 (95% CI: 0.94-1.33). 140 
As for the postoperative use of RASi, Drenger et al. [13] defined four groups, where 141 
“continuation” meant on ACEIs preoperatively and postoperatively; “withdrawal” denoted taking 142 
ACEIs preoperatively but not postoperatively; “addition” represented not on ACEIs preoperatively 143 
but had it added postoperatively; “no ACEIs” meant no exposure to ACEIs. When evaluating the 144 
effect of ACEIs in the continuation group versus the withdrawal group, the adjusted OR was 0.47 145 
(95% CI: 0.28-0.79), which indicated a possibly improved kidney outcome with the continuation 146 
of ACEIs.  For the comparison between the addition group and no ACEIs group, the OR was 0.57 147 
(95% CI: 0.24-1.36).  148 
Type of RASi and postoperative AKI 149 
Manning et al. [38] showed that ACEIs and ARBs worked differently and thus, led to different 150 
outcomes in their study. To understand the effects of different types of RASi, studies were divided 151 
into using ACEIs exclusively and using ACEIs/ARBs. No study solely used ARBs.  152 
The pooled OR of the 13 studies using ACEIs exclusively was 1.10 (95% CI: 0.92-1.32) (Figure 153 
S2, provided as online supplementary material). For the ten studies used ACEIs/ARBs, the pooled 154 
OR was 0.96 (95% CI: 0.81-1.14) (Figure S3). No significant association was found in both meta-155 
analyses 156 
Publication Bias 157 
The publication bias was examined by the funnel plot (Figure S4) and the Egger’s test. The bias 158 
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coefficient was -1.19 (95% CI: -3.05-0.67), P = 0.196; thus, no statistically significant publication 159 
bias was found. 160 
Sensitivity Analysis 161 
We performed the following sensitivity analysis with different subgroups of studies:  162 
• Since the confounders could bring bias, we restricted to the studies in which the 163 
confounders were matched by propensity score matching or adjusted through multivariate 164 
regression. The pooled OR was given in Figure S5. 165 
• We separated cohort studies from RCTs and performed the meta-analysis on both 166 
subgroups. The results were shown in Figures S6 and S7. 167 
• As CPB appeared to be one of the main reasons that the RAS activities were increased, we 168 
analyzed the subgroup of studies that included CPB (Figure S8). We also performed the 169 
meta-analysis in the subgroup of studies that only performed CABG (Figure S9). 170 
All of the subgroup analyses above showed no significant association between perioperative 171 
RASi therapy and postoperative AKI. 172 
Quality Assessment 173 
The risk of bias in cohort studies and RCTs were shown in Table 1. The RCTs were at low risk 174 
of bias. All observational studies scored four or more stars in the Newcastle–Ottawa scale, while 175 
11 of the 22 studies scored five or more. The common reasons for poor quality included: (1) lack 176 
of specific definition of the exposure, i.e., drug intervention; (2) lack of information of the history 177 
in renal function insufficiency; and (3) inconsistent assessment of outcomes. 178 
Discussion 179 
The meta-analysis of all included studies showed no significant association between 180 
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perioperative RASi therapy and postoperative AKI in patients undergoing cardiac surgery. 181 
Furthermore, the subgroup meta-analysis in two different patterns of RASi therapy (preoperative 182 
use of RASi versus no RASi, and preoperative continuation versus preoperative discontinuation) 183 
also demonstrated no significant association. Overall, there was no evidence of the increased or 184 
decreased risk of postoperative AKI when using RASi in patients undergoing cardiac surgery. 185 
This result contradicted with a meta-analysis published in 2013 by Yacoub et al. [6]. There were 186 
18 common studies included in our meta-analysis and [6]. Yacoub et al. found that the preoperative 187 
use of RASi was associated with increased odds of postoperative AKI in patients undergoing 188 
cardiothoracic surgery. However, their conclusion might be biased due to the choice of unadjusted 189 
OR instead of adjusted OR in several included studies [13, 15, 16, 17] while adjusted ORs were 190 
available. For example, Rady [15] concluded that preoperative therapy with ACEIs did not 191 
influence the AKI incidence based on the regression OR 0.9 (95% CI: 0.7-1.2); Yacoub et al.’s 192 
meta-analysis, however, used the unadjusted OR, which was 1.37 (95% CI: 1.08-1.73). One 193 
possible explanation of the higher OR before confounder adjustment was that some of the 194 
confounders were also risk factors of AKI, like hypertension, diabetes, obesity, and patients with 195 
such features were predisposed to AKI.  196 
Another meta-analysis by Cheungpasitporn et al. [18] studied a similar issue in patients 197 
undergoing all kinds of operations instead of only cardiac surgery. It showed no significant 198 
association between postoperative AKI and preoperative use of RASi in all included studies, while 199 
a reduced risk in studies with propensity score analysis. 200 
There were five RCTs reporting lab indices related to renal function. In 1990, an RCT with 18 201 
participants by Colson et al. [19] demonstrated that renal plasma flow and glomerular filtration rate 202 
decreased in the controlled group whereas remained unaltered in the treatment group. An RCT in 203 
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2001 [21] showed that the administration of RASi helped maintain renal perfusion during surgery. 204 
Wagner et al. [22] and Turker et al. [23] showed higher creatinine clearance and lower creatinine 205 
under RASi therapy. These results indicated a renoprotective effect of short-term RASi treatment 206 
in patients undergoing cardiac surgery. In 1999, Licker et al. [20] performed a case-control study 207 
and showed that renal functional and hemodynamic variables did not differ between the controlled 208 
and treatment group. Among studies that reported postoperative AKI, some showed a decreased 209 
risk of postoperative AKI [4, 12, 15, 17, 24, 25, 26]; some reported the opposite result [5, 14, 16, 210 
27, 28, 29, 30, 31, 32]; and others found no significant association between postoperative AKI and 211 
RASi therapy [11, 13, 33, 34, 35, 36, 37]. 212 
There were also studies investigating other outcomes of RASi. For example, some research 213 
showed that perioperative use of ACEI was associated with protracted vasoplegia before, during, 214 
and after CPB [39, 40]. A large multicentre study of 4,224 patients undergoing CABG showed that 215 
continuous treatment with ACEI compared with no ACEI was associated with reductions of risks 216 
of non-fatal events [13]. The addition of ACEI following surgery was also found to be associated 217 
with a significant reduction in both the risk of composite outcome and the risk of a cardiovascular 218 
event [13]. A clinical study showed that among patients undergoing transcatheter aortic valve 219 
replacement, receiving RASi compared with not receiving was significantly associated with a 220 
lower risk of mortality and heart failure readmission [41].  221 
Limitations 222 
There were several limitations to our study. First, the heterogeneity in our study was relatively 223 
high. The heterogeneity might arise from the study populations and different drug management 224 
practices. We tried to decrease the heterogeneity by classifying the studies for subgroup analysis. 225 
Unfortunately, the heterogeneity remained relatively high in all of the subgroup analyses. 226 
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Second, most included studies were cohort studies, and only two were RCTs, which were 227 
limited by their study designs. Van et al. [11] performed an RCT among 121 patients, and the 228 
number of patients who developed AKI was one in both treatment and control groups, which was 229 
quite small. In the other RCT [12], the definition of AKI was serum creatinine >2.5 mg/L, which 230 
was less commonly used. 231 
Third, the language included in the study was limited to English, and we did not identify 232 
unpublished studies. Thus, the studies included might be incomplete. 233 
Conclusion 234 
In conclusion, our results showed no significant association between perioperative RASi 235 
therapy and postoperative AKI, which was different from a previous meta-analysis on the same 236 
topic. The difference was largely due to our choice of adjusted OR rather than the unadjusted OR 237 
used in the previous meta-analysis. Our findings suggested that perioperative RASi management 238 
strategies did not have a statistically significant effect on the postoperative AKI incidence in 239 
patients undergoing cardiac surgery. Due to the limitations of existing studies, well-designed large-240 
scale RCTs are needed to verify the conclusion. 241 
 242 
  243 
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Figure Legend 351 
Figure 1: Flow diagram of study selection. AKI = acute kidney injury 352 
Figure 2: Forest plot of all the included studies comparing the risk of postoperative AKI in patients 353 
with and without perioperative use of RASi, using a random-effect model. A diamond data marker 354 
represents the overall odds ratio and 95% CI for the outcome. AKI = acute kidney injury; IV = 355 
inverse-variance; RASi = renin-angiotensin system inhibitors; SE = standard error; CI = confidence 356 
interval; df = degrees of freedom 357 
Figure 3: Forest plot of all the included studies comparing the risk of postoperative AKI in patients 358 
with and without preoperative use of RASi, using a random-effect model. A diamond data marker 359 
represents the overall odds ratio and 95% CI for the outcome. AKI = acute kidney injury; IV = 360 
inverse-variance; RASi = renin-angiotensin system inhibitors; SE = standard error; CI = confidence 361 
interval; df = degrees of freedom 362 
Figure 4: Graphical abstract of the meta-analysis. No significant association between perioperative 363 
RASi therapy and postoperative AKI in patients undergoing cardiac surgery was observed with OR 364 
being 1.02 (95% CI: 0.89-1.17). RASi = renin-angiotensin system inhibitors; OR = odds ratio 365 
Figure S1: Forest plot of all the included studies comparing the risk of postoperative AKI in patients 366 
with the preoperative continuation of RASi and with preoperative withdrawal, using a random-367 
effect model. A diamond data marker represents the overall odds ratio and 95% CI for the outcome. 368 
AKI = acute kidney injury; IV = inverse-variance; RASi = renin-angiotensin system inhibitors; SE 369 
= standard error; CI = confidence interval; df = degrees of freedom 370 
Figure S2: Forest plot of all the included studies comparing the risk of postoperative AKI in patients 371 
with ACEIs therapy and not with, using a random-effect model. AKI = acute kidney injury; IV = 372 
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inverse-variance; ACEIs = angiotensin-converting enzyme inhibitors; SE = standard error; CI = 373 
confidence interval; df = degrees of freedom 374 
Figure S3: Forest plot of all the included studies comparing the risk of postoperative AKI in patients 375 
with ACEIs/ARBs therapy and not with, using a random-effect model. AKI = acute kidney injury; 376 
IV = inverse-variance; ACEIs = angiotensin-converting enzyme inhibitors; ARBs = angiotensin II 377 
receptor blockers; SE = standard error; CI = confidence interval; df = degrees of freedom 378 
Figure S4: Funnel plot of publication bias 379 
Figure S5: Forest plot of all the matched or adjusted studies comparing the risk of postoperative 380 
AKI in patients with perioperative RASi therapy and not with, using a random-effect model. AKI 381 
= acute kidney injury; IV = inverse-variance; RASi = renin-angiotensin system inhibitors; SE = 382 
standard error; CI = confidence interval; df = degrees of freedom 383 
Figure S6: Forest plot of all the observational studies comparing the risk of postoperative AKI in 384 
patients with perioperative RASi therapy and not with, using a random-effect model. AKI = acute 385 
kidney injury; IV = inverse-variance; RASi = renin-angiotensin system inhibitors; SE = standard 386 
error; CI = confidence interval; df = degrees of freedom 387 
Figure S7: Forest plot of all the randomized controlled trials comparing the risk of postoperative 388 
AKI in patients with perioperative RASi therapy and not with, using a random-effect model. AKI 389 
= acute kidney injury; IV = inverse-variance; RASi = renin-angiotensin system inhibitors; SE = 390 
standard error; CI = confidence interval; df = degrees of freedom 391 
Figure S8: Forest plot of all the studies where the surgery uses cardiopulmonary bypass comparing 392 
the risk of postoperative AKI in patients with perioperative RASi therapy and not with, using a 393 
random-effect model. AKI = acute kidney injury; IV = inverse-variance; RASi = renin-angiotensin 394 
 20 
system inhibitors; SE = standard error; CI = confidence interval; df = degrees of freedom 395 
Figure S9: Forest plot of all the studies where the surgery is isolated CABG comparing the risk of 396 
postoperative AKI in patients with perioperative RASi therapy and not with, using a random-effect 397 
model. AKI = acute kidney injury; IV = inverse-variance; RASi = renin-angiotensin system 398 
inhibitors; SE = standard error; CI = confidence interval; df = degrees of freedom; CABG = 399 
coronary artery bypass graft 400 
  401 
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CABG using CPB 






































Taking ACEIs until 
the surgery day  
SCr  >2 mg/dL or an 
increase of 50% from 
baseline  
Intervention: 















Chronic use of 
ACEIs/ARBs 
preoperatively 
Increase in SCr >2 
mg/dL, doubling of 
preoperative SCr level 
or new requirement 
for dialysis 
Intervention: 
















Two or more weeks 
of ACEIs therapy 
until the day of 
operation 
50% or more decrease 
in the GFR 
Intervention: 












Chronic use of 
ACEIs, ACEIs is 
withdrawn the day 
before surgery and 
restarted the day 
after surgery 
A 20% decrease in 
GFR between day 0 
(before surgery) and 



















versus no ACEIs; 
On ACEIs  
postoperatively 
versus no ACEIs 
A postoperative SCr 
of at least 177 μmol/L 
accompanied by an 
increase of at least 62 















No preoperative use 
of ACEIs/ARBs vs. 
on them within 30 
days until the 
surgery morning vs. 
on them but held on 
surgery morning  
At least a change in 
SCr of 50% or 0.3 
mg/dL from baseline 


















On ACEIs for more 
than two weeks 
before surgery  
(1)Decrease ≥50% in 
GFR and creatinine 
clearance of 80 
mL/dk/1.73 m2 
(2)Blood urea 

























≥25% decrease in 
GFR within one week 
after surgery or 



















On ACEIs before 
surgery and 
continued to the day 
of surgery  
More than 25% 
increase in SCr, SCr > 
2.0 mg/dL within 72 h 
after surgery  
Intervention: 














preoperative use of 
ACEIs 
More than 50% 
postoperative increase 
in SCr from baseline  














Preoperative use of 
ACEIs within 24h 
before surgery 
An SCr 200 μmol/l 
plus an increase of at 


















Preoperative use of 
ACEIs/ARBs  
Creatinine exceeding 
176 μmol/L and 
showing more than a 
50% increase from its 
preoperative level  
Intervention: 













7 to 4 days before 
surgery, patients 
were randomized to 
treatment with 
placebo, ramipril 
Scr more than 
2.5mg/dL 
Intervention: 






CABG or valve 




Preoperative use of 
ACEIs 
More than 30% 
increase in SCr within 

















for > 2 weeks and 
within 24 h before 
surgery  
Increase in SCr 
of >0.5 mg/dL or 
more than 50% from 
baseline 
Intervention: 
















within 30 days with 
the last dose given 
within in 24 h 
before surgery 
SCr >2 mg/dL  
Intervention: 







All admissions to 
an ICU after 




More than two 
weeks of treatment 
with ACEIs on a 
standard dosage 
schedule before the 
date of surgery 
Postoperative SCr 
larger than 3.8 mg/dL, 
doubling of SCr if the 
preoperative value 
was >1.9 mg/ dL or 
requirement for renal 
replacement therapy 
Intervention: 














re to ACEIs within 


















for ≥2 weeks before 
surgery  
Increase in SCr of  > 
0.3 mg/dL or >50% 
from baseline within 
48 h after surgery 
Intervention: 










age >18, treated 
with ACEIs/ARBs 





days before surgery 
A doubling of SCr or 
a >50% decline in 
GFR 
Intervention: 














for at least 2 weeks 
and continue to the 
surgery day  
Increase in SCr of 0.3 
mg/dL or 50% from 
baseline  




ACEIs = angiotensin-converting enzyme inhibitors; ARBs = ngiotensin II receptor blockers; CABG = coronary artery 403 
bypass graft; CPB = cardiopulmonary bypass; GFR = glomerular filtration rate; RCT = randomized controlled trials; 404 
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RIFLE = risk, injury, failure, loss, ESRD; SCr = Serum creatinine 405 
